|
12 Jun 2015 |
ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme
|
|
11 Jun 2015 |
Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
|
|
11 Jun 2015 |
Celyad Completes 30-Day Safety Follow-Up of First Patient in NKG2D Phase I Trial
|
|
11 Jun 2015 |
Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells
|
|
09 Jun 2015 |
FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica's itMSC Therapy to Treat Alzheimer's Disease
|
|
09 Jun 2015 |
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
|
|
08 Jun 2015 |
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics
|
|
08 Jun 2015 |
BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
|
08 Jun 2015 |
Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
|
